SARMs LGD 4033

Selective Androgen Receptor Modulators (SARMs) provide the benefits of traditional anabolic/androgenic steroids such as testosterone (including increased muscle mass, fat loss, and bone density) while having a lower tendency to produce the unwanted side effects of steroids (aromatization / increased DHT). By acting/stimulating on the androgen receptor, SARMs can provide a similar therapeutic outcome to androgen therapy without any increase in androgen levels. SARMs have the potential to take the place of the androgens, and therefore exert many of the same positive effects on muscle tissue as anabolic steroids like testosterone. SARM 4033 (Ligandrol) is administered orally and is not liver toxic like most oral steroids are. The anabolic effect has been measured to be roughly the same as testosterone. It has also been shown to produce dose-dependent increases in bone mineral density and mechanical strength in addition to being able to decrease body fat and increase lean body mass.

Benefits of SARMs:

  • Provides benefits of anabolic/androgenic steroids such as testosterone
  • Increased fat loss
  • Increased lean muscle mass
  • Increased bone density
  • Fewer side effects compared to steroids, including prostate and cardiovascular outcomes
  • Not liver toxic like other oral steroids
  • Anabolic effect noted to be similar to testosterone

Side Effects:

Some studies have shown that SARM LGD 4033 (Ligandrol) can heavily suppress and lower free testosterone levels while also suppressing and lowering sex hormone binding globulin (SHBG) levels. However, the good news is that after taking LGD-4033 it will only take a very short time (1 to 3 weeks) for your testosterone levels to get back to normal. Getting back to normal doesn’t take much time because Ligandrol does not affect LH or FSH. There have also been no reported estrogenic system changes reported after taking LGD 4033. 

Research:

J Gerontol A Biol Sci Med Sci. 2013 Jan;68(1):87-95. doi: 10.1093/gerona/gls078. Epub 2012 Mar 28.

The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.